{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:34:58Z","timestamp":1793230498648,"version":"4.5.0"},"reference-count":53,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T00:00:00Z","timestamp":1470182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>Fungal diseases of the nail bed (onychomycosis) and epidermis are recurrent illnesses in the elderly and immunocompromised patients, which have few efficacious treatment options. Current treatment options for onychomycosis are limited to topical agents, laser treatment, and oral antifungals. Previous generations of topical agents were not efficacious, owing to poor penetration of the nail bed. Oral antifungal drugs, such as itraconazole, terbinafine, and fluconazole, not only give better response rates but also inhibit a host of CYP450 enzymes. Oral antifungals can exacerbate drug\u2013drug interactions for patients taking other medications concurrently. Newer topical agents might recognize improved efficacy and provide therapeutic alternatives when the use of oral antifungal agents is contraindicated. Recently, the Food and Drug Administration (FDA) approved efinaconazole and tavaborole for the treatment of onychomycosis. Additionally, the FDA approved luliconazole for the treatment of tinea pedis, tinea cruris, and tinea corporis. This review examines the mechanism of action, spectrum of activity, pharmacokinetics, and clinical trials data and considers the place in therapy for these 3 new antimycotic agents.<\/jats:p>","DOI":"10.1177\/0897190016660487","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T20:38:27Z","timestamp":1470256707000},"page":"621-630","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":43,"title":["Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi"],"prefix":"10.1177","volume":"30","author":[{"given":"Jacqueline","family":"Saunders","sequence":"first","affiliation":[{"name":"College of Pharmacy, Ferris State University, Big Rapids, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Maki","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ferris State University, Big Rapids, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Koski","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ferris State University, Big Rapids, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Eric","family":"Nybo","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ferris State University, Big Rapids, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,8,3]]},"reference":[{"key":"bibr1-0897190016660487","first-page":"1","author":"Dowd FJ","year":"2011","journal-title":"xPharm Compr Pharmacol Ref"},{"key":"bibr2-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107754"},{"key":"bibr3-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.12.006"},{"key":"bibr4-0897190016660487","doi-asserted-by":"crossref","unstructured":"Hayette MP, Sacheli R. Dermatophytosis, trends in epidemiology and diagnostic approach. Current Fungal Infection Reports [Internet]. 2015;9(3):164\u2013179. Web site. http:\/\/link.springer.com\/10.1007\/s12281-015-0231-4. Accessed April 1, 2016.","DOI":"10.1007\/s12281-015-0231-4"},{"key":"bibr5-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80300-9"},{"key":"bibr6-0897190016660487","unstructured":"Carroll KC, Hobden JA, Miller S, Medical Mycology. Jawetz, Melnick, & Adelberg\u2019s Medical Microbiology, 27e [Internet]. New York, NY: McGraw-Hill Education; 2015. Web site. http:\/\/mhmedical.com\/content.aspx?aid=1114738831. Accessed April 1, 2016."},{"key":"bibr7-0897190016660487","doi-asserted-by":"crossref","unstructured":"Choudhary S, Bisati S, Singh A, Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. Indian J Dermatol [Internet]. 2013;58(6):457\u2013460. Web site. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3827518&tool=pmcentrez&rendertype=abstract. Accessed April 1, 2016.","DOI":"10.4103\/0019-5154.119958"},{"key":"bibr8-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70483-9"},{"key":"bibr9-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00035-4"},{"key":"bibr10-0897190016660487","doi-asserted-by":"crossref","unstructured":"Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev [Internet]. 1998;11(3):415\u2013429. Web site. http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9665975. Accessed April 1, 2016.","DOI":"10.1128\/CMR.11.3.415"},{"key":"bibr11-0897190016660487","doi-asserted-by":"crossref","unstructured":"Ameen M, Lear JT, Madan V, British Association of Dermatologists\u2019 guidelines for the management of onychomycosis 2014. Br J Dermatol [Internet]. 2014;171(5):937\u2013958. Web site. http:\/\/dx.doi.org\/10.1111\/bjd.13358. Accessed April 1, 2016.","DOI":"10.1111\/bjd.13358"},{"key":"bibr12-0897190016660487","doi-asserted-by":"crossref","unstructured":"Jiaravuthisan MM, Sasseville D, Vender RB, Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol [Internet]. 2007;57(1):1\u201327. Web site. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0190962205032287. Accessed April 1, 2016.","DOI":"10.1016\/j.jaad.2005.07.073"},{"key":"bibr13-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"bibr14-0897190016660487","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.50.207"},{"key":"bibr15-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2.3.435"},{"key":"bibr16-0897190016660487","doi-asserted-by":"crossref","unstructured":"St\u00fcttgen G, Bauer E. Bioavailability, skin- and nailpenetration of topically applied antimycotics. Mycoses [Internet]. Blackwell Publishing Ltd; 1982;25(2):74\u201380. Web site. http:\/\/dx.doi.org\/10.1111\/j.1439-0507.1982.tb02721.x. Accessed April 1, 2016.","DOI":"10.1111\/j.1439-0507.1982.tb02721.x"},{"key":"bibr17-0897190016660487","unstructured":"Anacor Pharmaceuticals Inc. Kerydin [package insert]. Palo Alto, CA; 2014."},{"key":"bibr18-0897190016660487","doi-asserted-by":"crossref","unstructured":"Baker SJ, Zhang Y-K, Akama T, Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem [Internet]. American Chemical Society. 2006;49(15):4447\u20134450. Web site. http:\/\/0-pubs.acs.org.libcat.ferris.edu\/doi\/abs\/10.1021\/jm0603724. Accessed April 1, 2016.","DOI":"10.1021\/jm0603724"},{"key":"bibr19-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1021\/jm050676a"},{"key":"bibr20-0897190016660487","unstructured":"Pharmacyclics Inc. Prescribing Information. 2014."},{"key":"bibr21-0897190016660487","unstructured":"Elewski BE, Aly R, Baldwin SL, Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol [Internet]. 2015;1\u20138. Web site. http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215015121. Accessed April 1, 2016."},{"key":"bibr22-0897190016660487","doi-asserted-by":"crossref","unstructured":"Adamczyk-Wo\u017aniak A, Cabaj MK, Dominiak PM, The influence of fluorine position on the properties of fluorobenzoxaboroles. Bioorg Chem [Internet]. 2015;60:130\u2013135. Web site. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0045206815000425. Accessed April 1, 2016.","DOI":"10.1016\/j.bioorg.2015.05.004"},{"key":"bibr23-0897190016660487","doi-asserted-by":"crossref","unstructured":"Elsayed MM. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective. J Control Release [Internet]. Elsevier B.V. 2015;199:132\u2013144. Web site. http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914007652. Accessed April 1, 2016.","DOI":"10.1016\/j.jconrel.2014.11.017"},{"key":"bibr24-0897190016660487","doi-asserted-by":"crossref","unstructured":"Markham A. Tavaborole: first global approval. Drugs [Internet]. 2014;74(13):1555\u20131558. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25118637. Accessed April 1, 2016.","DOI":"10.1007\/s40265-014-0276-7"},{"key":"bibr25-0897190016660487","doi-asserted-by":"crossref","unstructured":"Tatsumi Y, Yokoo M, Arika T, In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother [Internet]. 2001;45(5):1493\u20131499. Web site. http:\/\/aac.asm.org\/content\/45\/5\/1493.long. Accessed April 1, 2016.","DOI":"10.1128\/AAC.45.5.1493-1499.2001"},{"key":"bibr26-0897190016660487","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.47.299"},{"key":"bibr27-0897190016660487","doi-asserted-by":"crossref","unstructured":"Sugiura K, Sugimoto N, Hosaka S, The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother [Internet]. 2014;58(7):3837\u2013342. Web site. http:\/\/aac.asm.org\/cgi\/doi\/10.1128\/AAC.00111-14. Accessed April 1, 2016.","DOI":"10.1128\/AAC.00111-14"},{"key":"bibr28-0897190016660487","doi-asserted-by":"crossref","unstructured":"Niwano Y, Kuzuhara N, Kodama H, In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother [Internet]. 1998;42(4):967\u2013970. Web site. http:\/\/aac.asm.org\/content\/42\/4\/967.long. Accessed April 1, 2016.","DOI":"10.1128\/AAC.42.4.967"},{"key":"bibr29-0897190016660487","doi-asserted-by":"crossref","unstructured":"Koga H, Nanjoh Y, Makimura K, In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol [Internet]. 2009;47(6):640\u2013647. Web site. http:\/\/informahealthcare.com\/doi\/abs\/10.1080\/13693780802541518. Accessed April 1, 2016.","DOI":"10.1080\/13693780802541518"},{"key":"bibr30-0897190016660487","doi-asserted-by":"crossref","unstructured":"Hui X, Baker SJ, Wester RC, In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci [Internet]. 2007;96(10):2622\u20132631. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17621679. Accessed April 1, 2016.","DOI":"10.1002\/jps.20901"},{"key":"bibr31-0897190016660487","doi-asserted-by":"crossref","unstructured":"Elewski BE, Aly R, Baldwin SL, Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol [Internet]. 2015;73(1):62\u201369. Web site. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0190962215015121. Accessed April 1, 2016.","DOI":"10.1016\/j.jaad.2015.04.010"},{"key":"bibr32-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02063-12"},{"key":"bibr33-0897190016660487","doi-asserted-by":"crossref","unstructured":"Jones T, Tavakkol A. Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis. Antimicrob Agents Chemother [Internet]. 2013;57(6):2684\u20132689. Web site. http:\/\/aac.asm.org\/content\/57\/6\/2684.short. Accessed April 1, 2016.","DOI":"10.1128\/AAC.02370-12"},{"key":"bibr34-0897190016660487","doi-asserted-by":"crossref","unstructured":"Watanabe S, Takahashi H, Nishikawa T, Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis\u2014comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses [Internet]. 2007;50(1):35\u201340. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17302746. Accessed April 1, 2016.","DOI":"10.1111\/j.1439-0507.2006.01305.x"},{"key":"bibr35-0897190016660487","unstructured":"Valeant Pharmaceuticals North America LLC. Jublia [package insert]. 2014; Web site. http:\/\/www.accessdata.fda.gov\/spl\/data\/7f5463f7-d06c-4e96-abb6-969737664e02\/7f5463f7-d06c-4e96-abb6-969737664e02.xml. Accessed April 1, 2016."},{"key":"bibr36-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.919852"},{"key":"bibr37-0897190016660487","doi-asserted-by":"publisher","DOI":"10.3109\/13693780903373811"},{"key":"bibr38-0897190016660487","doi-asserted-by":"crossref","unstructured":"Jo Siu WJ, Tatsumi Y, Senda H, Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother [Internet]. 2013;57(4):1610\u20131616. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23318803. Accessed April 1, 2016.","DOI":"10.1128\/AAC.02056-12"},{"issue":"4","key":"bibr39-0897190016660487","first-page":"203","volume":"92","author":"Tosti A","year":"2013","journal-title":"Cutis"},{"issue":"11","key":"bibr40-0897190016660487","first-page":"1388","volume":"13","author":"Sakamoto M","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"bibr41-0897190016660487","unstructured":"Valeant Pharmaceuticals North America LLC. Jublia [package insert]. Bridgewater, NJ; 2014."},{"key":"bibr42-0897190016660487","doi-asserted-by":"crossref","unstructured":"Elewski BE, Rich P, Pollak R, Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol [Internet]. 2013;68(4):600\u2013608. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23177180. Accessed April 1, 2016.","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"bibr43-0897190016660487","unstructured":"Valeant Pharmaceuticals North America LLC. LUZU [package insert]. Bridgewater, NJ; 2013. Web site. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204153s000lbl.pdf. Accessed April 1, 2016."},{"key":"bibr44-0897190016660487","doi-asserted-by":"crossref","unstructured":"Koga H, Tsuji Y, Inoue K, In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother [Internet]. 2006;12(3):163\u2013165. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16826352. Accessed April 1, 2016.","DOI":"10.1007\/s10156-006-0440-4"},{"key":"bibr45-0897190016660487","doi-asserted-by":"crossref","unstructured":"Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses [Internet]. 2014;57(7):389\u2013393. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24621346. Accessed April 1, 2016.","DOI":"10.1111\/myc.12168"},{"key":"bibr46-0897190016660487","doi-asserted-by":"crossref","unstructured":"Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother [Internet]. 2004;10(4):216\u2013219. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15365862. Accessed April 1, 2016.","DOI":"10.1007\/s10156-004-0327-1"},{"key":"bibr47-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05255-11"},{"key":"bibr48-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01218.x"},{"key":"bibr49-0897190016660487","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02706-13"},{"key":"bibr50-0897190016660487","unstructured":"Ely JW, Rosenfeld S, Stone MS. Diagnosis and management of tinea infections. Am Fam Physician [Internet]. 2014;90(10):702\u2013710. Web site. http:\/\/www.aafp.org\/afp\/2014\/1115\/p702.html. Accessed April 1, 2016."},{"key":"bibr51-0897190016660487","doi-asserted-by":"crossref","unstructured":"El-Gohary M, van Zuuren EJ, Fedorowicz Z, Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev [Internet]. 2014;8:CD009992. Web site. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25090020. Accessed April 1, 2016.","DOI":"10.1002\/14651858.CD009992.pub2"},{"issue":"11","key":"bibr52-0897190016660487","first-page":"762","volume":"88","author":"Westerberg DP","year":"2013","journal-title":"Am Fam Physician"},{"key":"bibr53-0897190016660487","doi-asserted-by":"crossref","unstructured":"Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol [Internet]. Blackwell Science Ltd; 2004;150(3):537\u2013544. Web site. http:\/\/dx.doi.org\/10.1046\/j.1365-2133.2003.05728.x. Accessed April 1, 2016.","DOI":"10.1046\/j.1365-2133.2003.05728.x"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190016660487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190016660487","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190016660487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:36Z","timestamp":1777509396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190016660487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,3]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1177\/0897190016660487"],"URL":"https:\/\/doi.org\/10.1177\/0897190016660487","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,3]]}}}